Streptomyces rochei strain:Xma-200 Genome sequencing
Candida infections remain a significant clinical challenge, particularly due to increasing antifungal resistance and the limitations of current treatment options. Many conventional antifungal agents, especially polyene drugs, are associated with considerable adverse effects, which can restrict their therapeutic use and negatively impact patient outcomes. Marine Actinomycetota represent a promising source of structurally diverse secondary metabolites with potent biological activities. The identification of safer, non-polyene antifungal agents could provide alternative treatment strategies and contribute to improving the clinical management of Candida-associated infections.This study aims to investigate bioactive compounds with anticandidal activity derived from marine Actinomycetota isolates obtained from Moroccan coastlines. The research specifically focuses on identifying non-polyene antifungal compounds that can be exploited to effectively manage Candida-associated diseases.